Psilocybin
Names | |
---|---|
Preferred IUPAC name
3-[2-(Dimethylamino)ethyl]-1H-indol-4-yl dihydrogen phosphate | |
Identifiers | |
3D model (
JSmol ) |
|
273158 | |
ChEBI | |
ChEMBL | |
ChemSpider | |
ECHA InfoCard
|
100.007.542 |
EC Number |
|
KEGG | |
MeSH | Psilocybine |
PubChem CID
|
|
RTECS number
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Pharmacology | |
Low | |
intravenous
| |
Pharmacokinetics: | |
Hepatic | |
Oral: 163±64 min Intravenous: 74.1±19.6 min[1] | |
Renal
| |
Legal status |
|
Properties | |
C12H17N2O4P | |
Molar mass | 284.252 g·mol−1 |
Melting point | 220–228 °C (428–442 °F)[3] |
Soluble | |
Solubility | Soluble in boiling methanol and water slightly soluble in ethanol insoluble in chloroform, benzene[4] |
Hazards | |
Lethal dose or concentration (LD, LC): | |
LD50 (median dose)
|
285 mg/kg (mouse, i.v.) 280 mg/kg (rat, i.v.) 12.5 mg/kg (rabbit, i.v.)[3] |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Psilocybin[a] (/ˌsaɪləˈsaɪbɪn/ sy-lə-SY-bin, /ˌsɪl-/) is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. The most potent are members of genus Psilocybe, such as P. azurescens, P. semilanceata, and P. cyanescens, but psilocybin has also been isolated from about a dozen other genera. Psilocybin is itself biologically inactive but is quickly converted by the body to psilocin, which has mind-altering effects similar, in some aspects, to those of lysergic acid diethylamide (LSD), mescaline, and dimethyltryptamine (DMT). In general, the effects include euphoria, visual and mental hallucinations, changes in perception, distorted sense of time, and perceived spiritual experiences. It can also cause adverse reactions such as nausea and panic attacks.
Imagery found on cave paintings and rock art of modern-day Spain and Algeria suggests that human use of psilocybin mushrooms predates recorded history. In Mesoamerica, the mushrooms had long been consumed in spiritual and divinatory ceremonies before Spanish chroniclers first documented their use in the sixteenth century. In 1958, the Swiss chemist Albert Hofmann isolated psilocybin and psilocin from the mushroom Psilocybe mexicana. Hofmann's employer Sandoz marketed and sold pure psilocybin to physicians and clinicians worldwide for use in psychedelic therapy. Although the increasingly restrictive drug laws of the 1960s and the 1970s curbed scientific research into the effects of psilocybin and other hallucinogens, its popularity as an entheogen (spirituality-enhancing agent) grew in the next decade, owing largely to the increased availability of information on how to cultivate psilocybin mushrooms.
The intensity and duration of the effects of psilocybin are variable, depending on species or cultivar of mushrooms, dosage, individual physiology, and set and setting, as was shown in experiments led by Timothy Leary at Harvard University in the early 1960s. Once ingested, psilocybin is rapidly metabolized to psilocin, which then acts on serotonin receptors in the brain. The mind-altering effects of psilocybin typically last from two to six hours, although to individuals under the influence of psilocybin, the effects may seem to last much longer, since the drug can distort the perception of time. Possession of psilocybin-containing mushrooms has been outlawed in most countries, and psilocybin has been classified as a Schedule I controlled substance under the 1971 United Nations Convention on Psychotropic Substances.
History
Early
There is evidence to suggest that psychoactive mushrooms have been used by humans in religious ceremonies for thousands of years. 6,000-year-old
Although dozens of species of psychedelic mushrooms are found in Europe, there is little documented usage of these species in Old World history besides the use of Amanita muscaria among Siberian peoples.[11][12] The few existing historical accounts about psilocybin mushrooms typically lack sufficient information to allow species identification, and usually refer to the nature of their effects. For example, Flemish botanist Carolus Clusius (1526–1609) described the bolond gomba (crazy mushroom), used in rural Hungary to prepare love potions. English botanist John Parkinson included details about a "foolish mushroom" in his 1640 herbal Theatricum Botanicum.[13]: 10–12 The first reliably documented report of intoxication with Psilocybe semilanceata—Europe's most common and widespread psychedelic mushroom—involved a British family in 1799, who prepared a meal with mushrooms they had picked in London's Green Park.[13]: 16
Modern
American banker and amateur
Heim cultivated the mushrooms in France and sent samples for analysis to Albert Hofmann, a chemist employed by the Swiss pharmaceutical company Sandoz (now Novartis). Hofmann—who had synthesized lysergic acid diethylamide (LSD) in 1938—led a research group that isolated and identified the psychoactive alkaloids psilocybin and psilocin from Psilocybe mexicana, publishing their results in 1958.[10]: 128 The team was aided in the discovery process by Hofmann's willingness to ingest mushroom extracts to help verify the presence of the active compounds.[10]: 126–127
Next, Hofmann's team synthesized several structural analogs of these compounds to examine how these structural changes would affect psychoactivity. This research led to the development of ethocybin and CZ-74. Because the physiological effects of these compounds last only about three and a half hours (about half as long as psilocybin), they proved more manageable than the latter for use in psycholytic therapy.[16]: 237 Sandoz also marketed and sold pure psilocybin under the name Indocybin to clinicians and researchers worldwide.[9]: 166 There were no reports of serious complications when psilocybin was used in this way.[1]
In the early 1960s,
Despite the legal restrictions on psilocybin use, the 1970s witnessed the emergence of psilocybin as the "entheogen of choice".
Because of a lack of clarity about laws about psilocybin mushrooms, specifically in the form of sclerotia (also known as "truffles"), European retailers in the late 1990s and early 2000s commercialized and marketed them in
Reported effects
The effects of psilocybin are highly variable and depend on the mindset and environment in which the user has the experience, factors commonly referred to as set and setting. In the early 1960s, Timothy Leary and colleagues at Harvard University investigated the role of set and setting on the effects of psilocybin. They administered the drug to 175 volunteers from various backgrounds in an environment intended to be similar to a comfortable living room. 98 of the subjects were given questionnaires to assess their experiences and the contribution of background and situational factors. Individuals who had experience with psilocybin prior to the study reported more pleasant experiences than those for whom the drug was novel. Group size, dosage, preparation, and expectancy were important determinants of the drug response. In general, those in groups of more than eight felt that the groups were less supportive, and their experiences less pleasant. Conversely, smaller groups (fewer than six) were seen as more supportive and reported more positive reactions to the drug in those groups. Leary and colleagues proposed that psilocybin heightens suggestibility, making an individual more receptive to interpersonal interactions and environmental stimuli.[17] These findings were affirmed in a later review by Jos ten Berge (1999), who concluded that dosage, set, and setting were fundamental factors in determining the outcome of experiments that tested the effects of psychedelic drugs on artists' creativity.[30]
After ingesting psilocybin, the user may experience a wide range of emotional effects which can include: feelings of disorientation, lethargy, giddiness, euphoria, joy, and depression. In one study, 31% of volunteers given a high dose reported feelings of significant fear and 17% experienced transient paranoia.[31] In studies at Johns Hopkins among those given a moderate dose (but still enough to "give a high probability of a profound and beneficial experience"), negative experiences were rare, whereas one-third of those given a high dose experienced anxiety or paranoia.[32][33] Low doses can induce hallucinatory effects. Closed-eye hallucinations may occur, where the affected individual sees multicolored geometric shapes and vivid imaginative sequences.[34] Some individuals report synesthesia, such as tactile sensations when viewing colors.[35]: 175 At higher doses, psilocybin can lead to "intensification of affective responses, enhanced ability for introspection, regression to primitive and childlike thinking, and activation of vivid memory traces with pronounced emotional undertones".[27] Open-eye visual hallucinations are common, and may be very detailed although rarely confused with reality.[34]
A 2011
Physical effects
Common responses include
Psychiatric effects and perceptual disturbances
Psilocybin is known to strongly influence the subjective experience of the passage of time.[42] Users often feel as if time is slowed down, resulting in the perception that "minutes appear to be hours" or "time is standing still".[43] Studies have demonstrated that psilocybin significantly impairs subjects' ability to gauge time intervals longer than 2.5 seconds, impairs their ability to synchronize to inter-beat intervals longer than 2 seconds, and reduces their preferred tapping rate.[43][44] These results are consistent with the drug's role in affecting prefrontal cortex activity,[45] and the role that the prefrontal cortex is known to play in time perception.[46] However, the neurochemical basis of psilocybin's effects on the perception of time are not known with certainty.[47]
Users having a pleasant experience can feel a sense of connection to others, nature, and the universe; other perceptions and emotions are also often intensified. Users having an unpleasant experience (a "bad trip") describe a reaction accompanied by fear, other unpleasant feelings, and occasionally by dangerous behavior. In general, the phrase "bad trip" is used to describe a reaction that is characterized primarily by fear or other unpleasant emotions, not just transitory experience of such feelings. A variety of factors may contribute to a psilocybin user experiencing a bad trip, including "tripping" during an emotional or physical low or in a non-supportive environment (see: set and setting). Ingesting psilocybin in combination with other drugs, including alcohol, can also increase the likelihood of a bad trip.[31][48] Other than the duration of the experience, the effects of psilocybin are similar to comparable dosages of lysergic acid diethylamide (LSD) or mescaline. However, in the Psychedelics Encyclopedia, author Peter Stafford noted, "The psilocybin experience seems to be warmer, not as forceful and less isolating. It tends to build connections between people, who are generally much more in communication than when they use LSD."[16]: 273
Theory of mind network and default mode network
Psychedelics, including psilocybin, have been shown to affect different clusters of brain regions known as the theory of mind network (ToMN) and the default mode network (DMN).[49] The ToMN involves making inferences and understanding social situations based on patterns[50] whereas, the DMN relates more to introspection and one's sense of self.[49] The DMN in particular is related to increased rumination and worsening self-image in patients with major depressive disorder (MDD).[51] In studies done with single use Psilocybin, areas of the DMN showed decreased functional connectivity (communication between areas of the brain). This provides functional insight into the work of psilocybin in increasing one's sense of connection to their surrounds as the areas of the brain involved in introspection decrease in functionality under the effects of the drug.[52] Conversely, areas of the brain involved in the ToMN showed increased activity and functional activation in response to psychedelics. These results were not unique to psilocybin and there was no significant difference in brain activation found in similar trials of mescaline and LSD. Information and studies into the DMN and ToMN are relatively sparse and their connections to other psychiatric illnesses and use of psychedelics is still largely unknown. [49]
Group perceptions
Through further anthropological studies regarding "personal insights"[53] and the psycho-social effects of psilocybin, it can be seen in many traditional societies that powerful mind-active substances such as psilocybin are regularly "consumed ritually for therapeutic purposes or for transcending normal, everyday reality".[54] Positive effects that psilocybin has on individuals can be observed by taking on an anthropological approach and moving away from the Western bio-medical society; this is aided by the studies done by Leary.[55] Within certain traditional societies where the use of psilocybin is frequent for shamanic healing rituals, group collectives praise their guide, healer and shaman for helping alleviate them of pains, aches and hurt. They do this through a group ritual practice where participants, or just the guide, ingests psilocybin to help extract any "toxic psychic residues or sorcerous implants"[54] found in one's body. Group therapies using classic psychedelics are becoming more commonly used in the Western world in clinical practice. This may continue to grow as long providing the evidence remains indicative of safety and efficacy.[56] In social sense, the group is shaped by their experiences surrounding psilocybin and how they view the plant collectively. As mentioned in the anthropology article,[54] the group partakes in a "journey" together, thus adding to the spiritual, social body, where roles, hierarchies and gender are subjectively understood.[54]
Adverse effects
Most of the comparatively few fatal incidents reported in the literature that are associated with psychedelic mushroom usage involve the simultaneous use of other drugs, especially
Toxicity
Data is sparse, but in the decade leading up to 2020, an increasing number of psilocybin mushroom overdoses were recorded. Nonetheless, the number of events requiring hospitalization remain rare, and overdoses are generally mild and self-limiting. A review regarding the management of psychedelic overdoses suggested that psilocybin related overdose management should prioritize managing the immediate adverse effects, such as anxiety and paranoia, rather than specific pharmacological interventions, as its physiological toxicity tends to be rather limited.[59] One analysis of mushrooms used by people hospitalized from psilocybin poisoning found high concentrations of phenethylamine (PEA), which has also been detected in the urine of people who have used psilocybin mushrooms. It is hypothesized that PEA may intensify the effect of psilocybin poisoning.[59]
In rats, the
Psychiatric
Panic reactions can occur after consumption of psilocybin-containing mushrooms, especially if the ingestion is accidental or otherwise unexpected. Reactions characterized by violent behavior, suicidal thoughts,
The similarity of psilocybin-induced symptoms to those of schizophrenia has made the drug a useful research tool in behavioral and
Tolerance and dependence
Repeated use of psilocybin does not lead to
Cultural significance and "mystical" experiences
Psilocybin mushrooms have been and continue to be used in indigenous New World cultures in religious, divinatory, or spiritual contexts. Reflecting the meaning of the word entheogen ("the god within"), the mushrooms are revered as powerful spiritual sacraments that provide access to sacred worlds. Typically used in small group community settings, they enhance group cohesion and reaffirm traditional values.[83] Terence McKenna documented the worldwide practices of psilocybin mushroom usage as part of a cultural ethos relating to the Earth and mysteries of nature, and suggested that mushrooms enhanced self-awareness and a sense of contact with a "Transcendent Other"—reflecting a deeper understanding of our connectedness with nature.[84]
Psychedelic drugs can induce states of
In the 1962
A group of researchers from
A follow-up study conducted 14 months after the original psilocybin session confirmed that participants continued to attribute deep personal meaning to the experience. Almost one-third of the subjects reported that the experience was the single most meaningful or spiritually significant event of their lives, and over two-thirds reported it among their five most spiritually significant events. About two-thirds indicated that the experience increased their sense of well-being or life satisfaction.[89] Even after 14 months, those who reported mystical experiences scored on average 4 percentage points higher on the personality trait of Openness/Intellect; personality traits are normally stable across the lifespan for adults. Likewise, in a recent (2010) web-based questionnaire study designed to investigate user perceptions of the benefits and harms of hallucinogenic drug use, 60% of the 503 psilocybin users reported that their use of psilocybin had a long-term positive impact on their sense of well-being.[31][69]
While many recent studies have concluded that psilocybin can cause mystical-type experiences having substantial and sustained personal meaning and spiritual significance, not all the medical community agree. Paul R. McHugh, formerly director of the Department of Psychiatry and Behavioral Science at Johns Hopkins, responded as follows in a book review: "The unmentioned fact in The Harvard Psychedelic Club is that LSD, psilocybin, mescaline, and the like produce not a "higher consciousness" but rather a particular kind of "lower consciousness" known well to psychiatrists and neurologists—namely, 'toxic delirium.'"[97]
Available forms
Although psilocybin may be prepared synthetically, outside of the research setting it is not typically used in this form. The psilocybin present in certain species of mushrooms can be ingested in several ways: by consuming fresh or dried fruit bodies, by preparing an
Chemistry
Physical properties
Psilocybin is a naturally-occurring
Psilocybin is a white, crystalline solid that is soluble in water, methanol and ethanol but insoluble in nonpolar organic solvents such as chloroform and petroleum ether.[99]: 15 It has a melting point between 220–228 °C (428–442 °F),[60] and an ammonia-like taste.[100] Its pKa values are estimated to be 1.3 and 6.5 for the two successive phosphate hydroxy groups and 10.4 for the dimethylamine nitrogen, so it typically exists as a zwitterionic structure.[100] There are two known crystalline polymorphs of psilocybin, as well as reported hydrated phases.[101] Psilocybin rapidly oxidizes upon exposure to light—an important consideration when using it as an analytical standard.[102]
Laboratory synthesis
Albert Hofmann et al. were the first team to synthesize psilocybin in 1958. Since that time, various chemists have improved the methods for the laboratory synthesis and purification of psilocybin. In particular, Shirota et al. reported a novel method in 2003 for the synthesis of psilocybin at the gram scale from 4-hydroxyindole that does not require chromatographic purification. Fricke et al. described an enzymatic pathway for the synthesis of psilocybin and psilocin, publishing their results in 2017. Sherwood et al. significantly improved upon Shirota's method (producing at the kilogram scale while employing less expensive reagents), publishing their results in 2020.[103]
Biosynthesis
Isotopic labeling experiments from the 1960s suggested that the biosynthesis of psilocybin was a four-step process:[105]
- decarboxylation of tryptophan to tryptamine
- N,N-dimethylation of tryptamine at the N9 position to dimethyltryptamine
- 4-hydroxylation of dimethyltryptamine to psilocin
- O-phosphorylation of psilocin to psilocybin
More recent research has demonstrated that—at least in P. cubensis—O-phosphorylation is in fact the third step, and that neither dimethyltryptamine nor psilocin are intermediates.[104] The sequence of the intermediate steps has been shown to involve four enzymes (PsiD, PsiH, PsiK, and PsiM) in P. cubensis and P. cyanescens, although it is possible that the biosynthetic pathway differs between species.[99]: 12–13 [104] These enzymes are encoded in gene clusters in Psilocybe, Panaeolus, and Gymnopilus.[106]
Escherichia coli has been genetically modified to manufacture large amounts of psilocybin.[107] Psilocybin can be produced de novo in GM yeast.[108][109]
Pharmacology
Pharmacodynamics
Psilocybin is a psychoplastogen,[110][111][112] which refers to a compound capable of promoting rapid and sustained neuroplasticity.
Psilocybin is rapidly
Psilocybin induces region-dependent alterations in glutamate that may be associated with subjective experiences of ego dissolution.[116]
Pharmacokinetics
The effects of the drug begin 10–40 minutes after ingestion, and last 2–6 hours depending on dose, species, and individual metabolism.
Psilocybin is metabolized mostly in the
Analytical methods
Several relatively simple
Various chromatographic methods have been developed to detect psilocin in
Natural occurrence
Species | % psilocybin |
---|---|
P. azurescens | 1.78 |
P. serbica | 1.34 |
P. semilanceata | 0.98 |
P. baeocystis | 0.85 |
P. cyanescens | 0.85 |
P. tampanensis | 0.68 |
P. cubensis | 0.63 |
P. weilii
|
0.61 |
P. hoogshagenii | 0.60 |
P. stuntzii | 0.36 |
P. cyanofibrillosa | 0.21 |
P. liniformans | 0.16 |
Psilocybin is present in varying concentrations in over 200 species of
Both the caps and the stems contain psychoactive compounds, although the caps consistently contain more. The spores of these mushrooms do not contain psilocybin or psilocin.[127][145][146] The total potency varies greatly between species and even between specimens of a species collected or grown from the same strain.[147] Because most psilocybin biosynthesis occurs early in the formation of fruit bodies or sclerotia, younger, smaller mushrooms tend to have a higher concentration of the drug than larger, mature mushrooms.[148] In general, the psilocybin content of mushrooms is quite variable (ranging from almost nothing to 2.5% of the dry weight)[149][16]: 248 and depends on species, strain, growth and drying conditions, and mushroom size.[8]: 36–41, 52 Cultivated mushrooms have less variability in psilocybin content than wild mushrooms.[150] The drug is more stable in dried than fresh mushrooms; dried mushrooms retain their potency for months or even years,[8]: 51–5 while mushrooms stored fresh for four weeks contain only traces of the original psilocybin.[31]
The psilocybin contents of dried
Societal perception and current usage
Legal status
The
Psilocybin mushrooms are not regulated by UN treaties.[158] Many countries, however, have some level of regulation or prohibition of psilocybin mushrooms (for example, the US Psychotropic Substances Act, the UK Misuse of Drugs Act 1971, and the Canadian Controlled Drugs and Substances Act).
In some jurisdictions, Psilocybe spores are legal to sell and possess, because they contain neither psilocybin nor psilocin.[159][citation needed] In other jurisdictions, they are banned because they are items that are used in drug manufacture. A few jurisdictions (such as the US states of California, Georgia and Idaho) have specifically prohibited the sale and possession of psilocybin mushroom spores. Cultivation of psilocybin mushrooms is considered drug manufacture in most jurisdictions and is often severely penalized, though some countries and one US state (New Mexico) has ruled that growing psilocybin mushrooms does not qualify as "manufacturing" a controlled substance.[citation needed]Advocacy for tolerance
Despite being illegal in many typically Western countries, such as the UK, Australia and some US states, less conservative governments opt to nurture the legal use of psilocybin and other psychedelic drugs. In Amsterdam, Netherlands, authorities provide education and promotion on the safe use of psychedelic drugs, such as psilocybin, in an aim to reduce public harm.[160] Similarly, religious groups like America's Uniao do Vegetal, UDV,[161] use psychedelics in traditional ceremonies.[162] From 1 July 2023, the Australian medicines regulator has permitted psychiatrists to prescribe psilocybin for the therapeutic treatment of post-traumatic stress disorder.[163]
Advocates for legalization argue there is a lack of evidence of harm,
Usage
A 2009 national survey of drug use by the
In modern Mexico, traditional ceremonial use survives among several indigenous groups, including the
Research
Psilocybin has been a subject of clinical research since the early 1960s, when the Harvard Psilocybin Project evaluated the potential value of psilocybin as a treatment for certain personality disorders.[171] Beginning in the 2000s, psilocybin has been investigated for its possible role in the treatment of nicotine dependence, alcohol dependence, obsessive–compulsive disorder (OCD), cluster headache, cancer-related existential distress[103][172] anxiety disorders, and certain mood disorders.[9]: 179–81 [173][174] In 2018, the United States Food and Drug Administration (FDA) granted breakthrough therapy designation for psilocybin-assisted therapy for treatment-resistant depression.[175][176] A systematic review published in 2021 found that the use of psilocybin as a pharmaceutical substance was associated with reduced intensity of depression symptoms.[177] The role of psilocybin as a possible psychoplastogen is also being examined.[110][111][112]
See also
- List of entheogens
- O-Acetylpsilocin
- Psychedelic microdosing
- Psychoactive plant
- Stoned ape theory
- Soma (drink)
Explanatory notes
- dimethyltryptamine), psilocybine, psilocibin, psilocybinum, psilotsibin, psilocin phosphate ester, and indocybin.[5]
- Lycaeum, Mycotopia, The Shroomery, MushroomJohn and The Entheogen Review. Regional sites focusing on hallucinogenic mushrooms listed were Copenhagen Mushroom Link (Denmark), Champis (France), Daath (Hungary), Delysid (Spain), Enteogeneos (Portugal), Kouzelné houbičky (Czech Republic), Norshroom (Norway), Planetahongo (Spain), Svampinfo (Sweden), and Taikasieniforum (Finland). It also listed Magic-Mushrooms.net. The report detailed several additional sites selling spore printsin 2006, but noted that many of these had ceased operation.
- ^ One of the reported fatalities, that of a 22-year-old French man who died in 1993,[63] was later challenged in the literature by Jochen Gartz and colleagues, who concluded "the few reported data concerning the victim are insufficient to exclude other possible causes of the fatality".[64]
- ^ The academic communities' approval for the methodology employed is exemplified by the quartet of commentaries published in the journal Psychopharmacology titled "Commentary on: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual experience by Griffiths et al.", by HD Kleber (pp. 291–292), DE Nichols (pp. 284–286), CR Schuster (pp. 289–290), and SH Snyder (pp. 287–288).
- ^ Subjective effects are "feelings, perceptions, and moods personally experienced by an individual"; they are often assessed using methods of self-report, including questionnaires. Behavioral effects, in contrast, can be observed directly.[113]
References
Citations
- ^ S2CID 12656091.
- ^ Anvisa (July 24, 2023). "RDC Nº 804 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 804 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published July 25, 2023). Archived from the original on August 27, 2023. Retrieved August 27, 2023.
- ^ a b Merck Index, 11th Edition, 7942
- ^ "Psilocybine". PubChem, US National Library of Medicine. August 27, 2022. Retrieved August 29, 2022.
- National Library of Medicine. Archivedfrom the original on September 25, 2012. Retrieved December 4, 2011.
- S2CID 3955222.
- ^ Samorini, Giorgio (1992). "The oldest representations of hallucinogenic mushrooms in the world (Sahara Desert, 9000-7000 BP)". Integration. Zeitschrift für geistbewegende Pflanzen und Kultur. 2/3: 69–65.[permanent dead link]
- ^ ISBN 978-0-89815-839-7.
- ^ ISBN 978-1603582148.
- ^ ISBN 978-0979862229.
- .
- ISBN 978-0-88316-517-1.
- ^ ISBN 978-0-9653399-0-2.
- from the original on April 3, 2017. Retrieved February 27, 2016.
- ^ Heim R (1957). "Notes préliminaires sur les agarics hallucinogènes du Mexique" [Preliminary notes on the hallucination-producing agarics of Mexico]. Revue de Mycologie (in French). 22 (1): 58–79.
- ^ ISBN 978-0-914171-51-5.
- ^ S2CID 39777572.
- doi:10.1037/h0088612.
- PMID 18593734. Archived from the original(PDF) on November 20, 2017. Retrieved November 20, 2017.
- ^ .
- ^ "The War on Drugs turns 50 today. It's time to make peace". The Washington Post. Retrieved August 8, 2023.
- doi:10.1038/scientificamerican1210-76. Archived from the original(PDF) on October 3, 2011. Retrieved July 25, 2011.
- ^ ISBN 978-0-9614234-3-8.
- ISBN 978-0-932551-06-1.
- from the original on September 23, 2015. Retrieved September 7, 2011.
- ^ ISBN 92-9168-249-7. Archived(PDF) from the original on March 29, 2012. Retrieved September 8, 2011.
- ^ S2CID 22923427.
- ^ Keim B (July 1, 2008). "Psilocybin study hints at rebirth of hallucinogen research". Wired.com. Archived from the original on August 3, 2011. Retrieved August 8, 2011.
- ^ Miller G (July 1, 2008). "A very memorable trip". sciencemag.org. Archived from the original on August 13, 2018. Retrieved August 8, 2011.
- ISSN 0022-0175.
- ^ PMID 21256914. Archived from the original(PDF) on January 9, 2015.
- ^ "Hallucinogenic Drug Psilocybin Eases Existential Anxiety in People With Life-Threatening Cancer". Johns Hopkins. December 1, 2016. Archived from the original on April 7, 2021. Retrieved April 9, 2019.
- PMID 21674151.
- ^ (PDF) from the original on April 18, 2020. Retrieved April 10, 2019.
- ^ ISBN 978-1-59454-961-8. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- ^ PMID 21956378.
- PMID 29020861.
- ^ "Psilocybin (from magic mushrooms) plus meditation and spiritual training leads to lasting changes in positive traits". January 19, 2018. Archived from the original on February 21, 2019. Retrieved February 21, 2019.
- (PDF) from the original on September 16, 2018. Retrieved December 27, 2011.
- ^ Quentin AM (1960). La Psilocybine en Psychiatrie Clinique et Experimentale [Psilocybin in Clinical and Experimental Psychiatry] (PhD thesis) (in French). Paris, France: Paris University Medical Dissertation.
- ^ See for example:
- Isbell H (1959). "Comparison of the reactions induced by psilocybin and LSD-25 in man". Psychopharmacologia. 1 (1): 29–38. S2CID 19508675.
- Hollister LE, Prusmack JJ, Paulsen A, Rosenquist N (1960). "Comparison of three psychotropic drugs (psilocybin, JB-329, and IT-290) in volunteer subjects". Journal of Nervous and Mental Disease. 131 (5): 428–434. S2CID 8255131.
- Malitz S, Esecover H, Wilkens B, Hoch PH (1960). "Some observations on psilocybin, a new hallucinogen, in volunteer subjects". Comprehensive Psychiatry. 1: 8–17. PMID 14420328.[permanent dead link]
- Isbell H (1959). "Comparison of the reactions induced by psilocybin and LSD-25 in man". Psychopharmacologia. 1 (1): 29–38.
- Rinkel M, Atwell CR, Dimascio A, Brown J (1960). "Experimental psychiatry. V. Psilocybine, a new psychotogenic drug". New England Journal of Medicine. 262 (6): 295–297. PMID 14437505.
- Parashos AJ (1976). "The psilocybin-induced "state of drunkenness" in normal volunteers and schizophrenics". Behavioral Neuropsychiatry. 8 (1–12): 83–86. PMID 1052267.
- ISBN 978-1-85070-569-7.
- ^ S2CID 3165579.
- S2CID 22789140.
- (PDF) from the original on August 16, 2019. Retrieved August 16, 2019.
- S2CID 25960626.
- ^ PMID 20668434.
- ^ PMID 18257429.
- ^ PMID 37467907.
- PMID 32360298.
- PMID 37261927.
- PMID 36272145.
- ^ "Drug Addictions, Hallucinogens and Shamanism: the View from Anthropology - Document - Gale Academic OneFile". Archived from the original on August 23, 2021. Retrieved August 23, 2021.
- ^ a b c d Batchelder T (2001). "Drug Addictions, Hallucinogens and Shamanism: the View from Anthropology". Drug Addictions, Hallucinogens and Shamanism. Townsend Letter for Doctors and Patients. 217: 74–77. Archived from the original on October 19, 2021. Retrieved August 23, 2021 – via Gale Academic OneFile.
- from the original on October 19, 2021. Retrieved August 23, 2021.
- PMID 33073220.
- ISBN 978-0-470-63906-1. Archivedfrom the original on April 3, 2017. Retrieved February 27, 2016.
- ISBN 978-0-444-50763-1. Archivedfrom the original on April 3, 2017. Retrieved February 27, 2016.
- ^ S2CID 220472473.
- ^ ISBN 978-0-911910-13-1.
- (PDF) from the original on August 10, 2006. Retrieved November 16, 2011.
- ISBN 978-1-59477-224-5. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- ^ Gérault A, Picart D (1996). "Intoxication mortelle à la suite de la consommation volontaire et en groupe de champignons hallucinogènes" [Fatal poisoning after a group of people voluntarily consumed hallucinogenic mushrooms]. Bulletin de la Société Mycologique de France (in French). 112: 1–14.
- ^ Gartz J, Samorini G, Festi F (1996). "On the presumed French case of fatality caused by ingestion of Liberty Caps". Eluesis. 6: 40–41. Archived from the original on April 5, 2012.
- S2CID 7453965.
- ^ S2CID 37706068. Archived from the original(PDF) on March 3, 2019.
- S2CID 20020560.
- PMID 6580536.
- ^ S2CID 56427651.
- S2CID 18506672.
- S2CID 44321700.
- S2CID 24647325.
- ^ S2CID 230298.
- PMID 19086254.
- ^ Myers LS, Watkins SS, Carter TJ (1998). "Flashbacks in theory and practice" (PDF). The Heffter Review of Psychedelic Research. 1: 51–57. Archived (PDF) from the original on September 27, 2011. Retrieved August 14, 2011.
- ISBN 978-0-7425-4245-7. Archivedfrom the original on January 7, 2012.
- ISBN 978-0-932551-71-9. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- PMID 19040555.
- ^ PMID 21256140.
- PMID 19022584.
- S2CID 207669364.
- S2CID 5667719.
- ISBN 978-0-275-99024-4.
- ISBN 978-0-553-37130-7.
- ISBN 978-0-684-84297-4.
- (PDF) from the original on September 21, 2017. Retrieved October 26, 2017.
- S2CID 18464414.
- ^ Pahnke WN (1966). "Drugs and mysticism". International Journal of Parapsychology. 8 (2): 295–315.
- ^ PMID 18593735. Archived from the original(PDF) on July 22, 2008. Retrieved July 3, 2008.
- ISBN 978-1-58542-034-6.
- ^ a b Doblin R (1991). "Pahnke's "Good Friday Experiment": a long-term follow-up and methodological critique". Journal of Transpersonal Psychology. 23 (1): 1–25.
- S2CID 144969540.
- S2CID 7845214. Archived from the original(PDF) on November 9, 2011.
- ^ "Press release: Griffiths psilocybin". Johns Hopkins Medicine. July 11, 2006. Archived from the original on July 16, 2011. Retrieved July 12, 2006.
- S2CID 147200008.
- ^ Smith M (July 12, 2006). "Medical News: Psilocybin Viewed as Therapy or Research Tool". Medpagetoday.com. Archived from the original on October 5, 2008. Retrieved February 12, 2011.
- ^ "Paul McHugh reviews Don Lattin's "The Harvard Psychedelic Club."". commentarymagazine.com. April 1, 2010. Archived from the original on April 10, 2019. Retrieved April 10, 2019.
- ISBN 978-0-12-374634-4. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- ^ S2CID 31056807.
- ^ a b "Psilocybine". Hazardous Substances Data Bank. U.S. National Library of Medicine. Archived from the original on August 13, 2018. Retrieved November 21, 2011.
- PMID 34982048.
- ^ PMID 17002211.
- ^ PMID 36678537.
- ^ PMID 28763571.
- PMID 5750023.
- ^ PMID 30283667.
- from the original on December 3, 2019. Retrieved December 3, 2019.
- PMID 32224264.
- PMID 35132076.
- ^ PMID 34671279.
- ^ PMID 30262987.
- ^ PMID 34566723.
- ISBN 978-1-4200-5458-3. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- ^ "PDSP Ki Database". PDSP. Archived from the original on May 9, 2021. Retrieved January 20, 2020.
- PMID 19799545.
- PMID 32446245.
- ^ PMID 11373000.
- PMID 12191719.
- PMID 21332315.
- ISBN 978-0-9626523-7-0.
- PMID 9491968.
- PMID 16884739.
- ISBN 978-1-890883-87-4. Archivedfrom the original on April 3, 2017. Retrieved February 27, 2016.
- ISBN 978-0-471-49252-8.
- ISBN 978-0-7234-1576-3. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- S2CID 45118221.
- ^ PMID 10077856.
- PMID 9252052.
- PMID 4040953.
- .
- .
- ^ PMID 9657222.
- ^ Rodriguez-Cruz SE (2005). "Analysis and characterization of psilocybin and psilocin using liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) with collision-induced-dissociation (CID) and source-induced dissociation (SID)". Microgram Journal. 3 (3–4): 175–82. Archived from the original on April 29, 2011.
- ^ PMID 10978655.
- PMID 2094720.
- PMID 14581081.
- S2CID 11249439.
- from the original on May 3, 2021. Retrieved August 24, 2020.
- ^ a b Guzmán G, Allen JW, Gartz J (2000). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion" (PDF). Annali del Museo Civico di Rovereto: Sezione Archeologia, Storia, Scienze Naturali. 14: 189–280. Archived (PDF) from the original on February 5, 2018. Retrieved October 19, 2021.
- ^ .
- ^ Yong E (August 24, 2017). "How Mushrooms Became Magic". The Atlantic. Archived from the original on March 16, 2018. Retrieved March 15, 2018.
- ISBN 978-3-7682-5474-8.
- from the original on March 10, 2017. Retrieved August 29, 2011.
- ^ Guzmán G, Allen JW, Gartz J (1998). "A worldwide geographical distribution of the neurotropic fungi, an analysis and discussion" (PDF). Annali del Museo Civico di Rovereto. 14: 207. Archived from the original (PDF) on June 26, 2010. Retrieved September 17, 2017.
- .
- PMID 2722990.
- ^ PMID 7201054.
- ^ Gartz J (1992). "New aspects of the occurrence, chemistry and cultivation of European hallucinogenic mushrooms". Supplemento Agli Annali dei Musei Civici di Rovereto Sezione Archeologica, Storia e Scienze Naturali. 8: 107–124.
- PMID 20047807.
- ^ "Drug profiles: Hallucinogenic mushrooms". European Monitoring Centre for Drugs and Drug Addiction. September 19, 2011. Archived from the original on November 27, 2011. Retrieved December 4, 2011.
- PMID 3430170.
- S2CID 38006957. Archived from the original(PDF) on November 16, 2020.
- ^ "List of psychotropic substances under international control" (PDF). International Narcotics Control Board. August 2003. Archived from the original (PDF) on December 5, 2005. Retrieved June 25, 2007.
- ^ Griffiths & Grob, Roland R. & Charles S. "Hallucinogens as Medicine" (PDF). Scientific American. Archived from the original (PDF) on October 3, 2011. Retrieved March 22, 2013.
- ^ Szalavitz, Maia (June 16, 2011). "'Magic Mushrooms' Can Improve Psychological Health Long Term". Time. Archived from the original on April 21, 2013. Retrieved March 22, 2013.
- PMID 21674151.
- ^ Jerome, Lisa. "Psilocybin Investigator's Brochure" (PDF). MAPS. Archived from the original (PDF) on March 19, 2013. Retrieved March 22, 2013.
- ^ Schaepe, Herbert (September 13, 2001). "UN's INCB Psilocybin Mushroom Policy". Erowid.org. Archived from the original on November 12, 2009. Retrieved January 7, 2012.
As you are aware, mushrooms containing the above substances are collected and used for their hallucinogenic effects. As a matter of international law, no plants (natural material) containing psilocin and psilocybin are at present controlled under the Convention on Psychotropic Substances of 1971. Consequently, preparations made of these plants are not under international control and, therefore, not subject of the articles of the 1971 Convention [emphasis added]. Criminal cases are decided with reference to domestic law, which may otherwise provide for controls over mushrooms containing psilocine and psilocybin. As the Board can only speak as to the contours of the international drug conventions, I am unable to provide an opinion on the litigation in question.
(Letter from Secretary of the UN International Narcotics Control Board to the Dutch Ministry of Health) - ^ "Psilocybin Spores are Not Controlled". Home Cultivation Association of New York. January 2, 2024. Retrieved March 19, 2024.
- S2CID 228997721.
- ^ ISBN 9788551004173.
- ISBN 978-1-4985-0910-7.
- ISSN 0261-3077. Retrieved July 18, 2023.
- ^ Submission to the Western Australian Inquiry Into Alternative Approaches to Reducing Illicit Drug Use and Its Effects on the Community (PDF) (Report). Australian Psychedelic Society Inc. January 30, 2019. Archived (PDF) from the original on August 23, 2021. Retrieved August 23, 2021.
- S2CID 2025731.
- PMID 29753748.
- S2CID 149858755.
- ISBN 978-1-60529-407-0. Archivedfrom the original on April 4, 2017. Retrieved February 27, 2016.
- ISBN 978-92-9168-470-0. Archived(PDF) from the original on December 3, 2011. Retrieved December 4, 2011.
- S2CID 22085876.
- PMID 19744846.
- PMID 36381758.
- PMID 27354908.
- PMID 27909164.
- ^ "COMPASS Pathways Receives FDA Breakthrough Therapy Designation for Psilocybin Therapy for Treatment-resistant Depression". Compass Pathways. Archived from the original on December 4, 2018. Retrieved December 3, 2018.
- ^ Richard Staines (December 2, 2019). "FDA tags psilocybin drug as clinical depression Breakthrough Therapy". Pharmaphorum. Archived from the original on September 7, 2021. Retrieved September 7, 2021.
- PMID 34451890.
External links
- Psilocybin Investigator's Brochure, Version 4.1 (Usona Institute, Madison, Wisconsin, 2021)